The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Liquidia Corporation (NASDAQ:LQDA) ranks 1st on this list.

Liquidia Corporation (NASDAQ:LQDA) first appeared in the 13F portfolio of Farallon Capital in the second quarter of 2020. Back then, this position comprised 1.8 million shares. The fund sold off this stake before the end of the year. A new position in the stock was then opened in the first quarter of 2024. This consisted of 2 million shares. Since then, the fund has added to this holding. Filings for the fourth quarter of 2025 show that the fund owned 8.6 million shares in the firm, up slightly compared to filings for the previous quarter. Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.

Photo by Arturo Añez on Unsplash

Liquidia Corporation (NASDAQ:LQDA) is viewed as a top-tier takeout candidate and a disruptive force in the pulmonary hypertension market. While the company faces ongoing litigation from its main rival, United Therapeutics, elite investors are focused on Liquidia’s transition into a profitable, billion-dollar franchise. The primary driver for institutional interest is the rapid adoption of YUTREPIA, Liquidia’s dry-powder treprostinil. In its Q4 2025 earnings, the firm reported $90.1 million in product sales for the quarter, a 74% sequential increase from Q3. Since its full launch in June 2025, Liquidia has captured a 17% share of the inhaled treprostinil market. Hedge funds are betting on this trend continuing as the company expands its sales force to target the over 860 active prescribers it has already engaged. CEO Roger Jeffs confirmed a clear path to becoming a $1 billion franchise by 2027.

While we acknowledge the potential of LQDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.